The design and development of highly effective antibacterial and anti-viral vaccines constitute one of IIBR's major areas of R&D expertise.
A wide spectrum of state-of-the-art methodologies, including in silico and proteomic genome-based antigen identification (see previous chapters), high throughput in vitro and in vivo screening systems, molecular analyses and biophysical characterization, provide the means to develop a new generation of safe and efficacious vaccines.
The expertise of our multi-disciplinary teams includes the development and production of:
- Attenuated viable vaccine strains (viral or bacterial)
- Subunit vaccines
- Purified proteins (native or recombinant)
- Recombinant proteins expressed in live vectors
- Hybrid virion vaccines
- DNA vaccines
- Specific antisera for passive immunotherapy
- Chimeric and fully humanized recombinant antibodies for passive immunotherapy
Vaccine development involves elucidation of diverse vaccine formulations and delivery systems to establish the means to confer efficacious and longterm immunity.
Vaccine evaluation systems are tailored for each pathogen/antigen of interest and include:
- Establishment of optimal in vitro or animal model systems
- Search for humoral and cellular correlates of immunity
- Determination of vaccine efficacy, potency and safety
Candidate vaccine testing for pre-clinical and clinical trials is carried out in accordance with the most updated Good Laboratory Practices (GLP)
|
|
|
|